Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KHK | P50053 | 8/20 | 0.62 |
| ▸ | HPGD | P15428 | 4/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 3/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.44 |
| ▸ | CDK2 | P24941 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | TNF | P01375 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.43 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13865930 | 0.88 | KHK (0.61) | KHKHPGDALDH1A1HTTTSHR | |
| SCHEMBL13865848 | 0.84 | HPGD (0.50) | KHKHPGDALDH1A1HTTTSHR | |
| SCHEMBL13865821 | 0.84 | HPGD (0.46) | KHKHPGDALDH1A1HTTTSHR | |
| SCHEMBL13865884 | 0.84 | KHK (0.60) | KHKHPGDALDH1A1HTTTSHR | |
| SCHEMBL13865894 | 0.82 | KHK (0.62) | KHKHPGDALDH1A1HTTTSHR | |
| SCHEMBL4507937 | 0.80 | KHK (0.59) | KHKHPGDALDH1A1HTTTSHR | |
| SCHEMBL13865892 | 0.79 | HPGD (0.54) | KHKHPGDALDH1A1HTTTSHR | |
| SCHEMBL4507115 | 0.76 | KHK (0.63) | KHKHPGDALDH1A1HTTCCNE1 | |
| Hydrochloric Acid SCHEMBL2551537 | 0.76 | KHK (0.98) | KHKHPGDALDH1A1HTTCCNE1 | |
| SCHEMBL2553474 | 0.75 | KHK (0.71) | KHKHPGDALDH1A1HTTCCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137549-A1 | Novel compounds useful for the treatment of degenerative & inflamatory diseases | GALAPAGOS NV (BE) | 2009-05-28 | — | — | US | disclosed |
| US-20090137549-A1 | Novel compounds useful for the treatment of degenerative & inflamatory diseases | GALAPAGOS NV (BE) | 2009-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137549-A1 | Novel compounds useful for the treatment of degenerative & inflamatory diseases | PDE4A, PDE7B, PDE4B | KHK 3420/4885HPGD 132/4885ALDH1A1 240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.